CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 41 enrolled
Drug / intervention
GIP +2 moredrug
Likely dose
Modified GIP 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00239707
NCT00239707Phase 1Completed
CompareCT.gov

Effect of GIP / GIP Analog in Type 2 Diabetes After a Meal

National Institute on Aging (NIA)·interventional·Posted Oct 17, 2005·Updated Nov 28, 2013

In Brief

A Phase 1 clinical trial evaluating GIP, Modified GIP, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2005
Enrollment StartFeb 1, 2003
Primary CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.7 years ago

Interventions

GIPdrug

One-time 20 ng/kg/min infusion over 3 hours

Modified GIPdrug

One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl

Normal Salinedrug

one-time infusion over 3 hours